166 related articles for article (PubMed ID: 12095169)
21. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination.
Pupa SM; Iezzi M; Di Carlo E; Invernizzi A; Cavallo F; Meazza R; Comes A; Ferrini S; Musiani P; Ménard S
Cancer Res; 2005 Feb; 65(3):1071-8. PubMed ID: 15705909
[TBL] [Abstract][Full Text] [Related]
22. Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies.
Dela Cruz JS; Trinh KR; Chen HW; Ribas A; Morrison SL; Penichet ML
Mol Immunol; 2006 Feb; 43(6):667-76. PubMed ID: 15908002
[TBL] [Abstract][Full Text] [Related]
23. Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse.
Singh R; Dominiecki ME; Jaffee EM; Paterson Y
J Immunol; 2005 Sep; 175(6):3663-73. PubMed ID: 16148111
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and therapeutic efficacy of a dual-component genetic cancer vaccine cotargeting carcinoembryonic antigen and HER2/neu in preclinical models.
Aurisicchio L; Peruzzi D; Koo G; Wei WZ; La Monica N; Ciliberto G
Hum Gene Ther; 2014 Feb; 25(2):121-31. PubMed ID: 24195644
[TBL] [Abstract][Full Text] [Related]
25. DNA vaccination against neu reduces breast cancer incidence and metastasis in mice.
Lachman LB; Rao XM; Kremer RH; Ozpolat B; Kiriakova G; Price JE
Cancer Gene Ther; 2001 Apr; 8(4):259-68. PubMed ID: 11393278
[TBL] [Abstract][Full Text] [Related]
26. Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine.
Orlandi F; Venanzi FM; Concetti A; Yamauchi H; Tiwari S; Norton L; Wolchok JD; Houghton AN; Gregor PD
Clin Cancer Res; 2007 Oct; 13(20):6195-203. PubMed ID: 17947487
[TBL] [Abstract][Full Text] [Related]
27. An HER2 DNA vaccine with evolution-selected amino acid substitutions reveals a fundamental principle for cancer vaccine formulation in HER2 transgenic mice.
Jones RF; Reyes JD; Gibson HM; Jacob JB; Vaishampayan U; Ratner S; Chen K; Wei WZ
Cancer Immunol Immunother; 2019 Jul; 68(7):1143-1155. PubMed ID: 31177328
[TBL] [Abstract][Full Text] [Related]
28. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector.
Gallo P; Dharmapuri S; Nuzzo M; Maldini D; Iezzi M; Cavallo F; Musiani P; Forni G; Monaci P
Int J Cancer; 2005 Jan; 113(1):67-77. PubMed ID: 15386429
[TBL] [Abstract][Full Text] [Related]
29. In vivo protein expression and immune responses generated by DNA vaccines expressing mycobacterial antigens fused with a reporter protein.
Quinn A; Jiang W; Velaz-Faircloth M; Cobb AJ; Henry SC; Frothingham R
Vaccine; 2002 Aug; 20(25-26):3187-92. PubMed ID: 12163270
[TBL] [Abstract][Full Text] [Related]
30. Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity.
Disis ML; Scholler N; Dahlin A; Pullman J; Knutson KL; Hellström KE; Hellström I
Mol Cancer Ther; 2003 Oct; 2(10):995-1002. PubMed ID: 14578464
[TBL] [Abstract][Full Text] [Related]
31. HER2/neu DNA vaccination for breast tumors.
Smorlesi A; Papalini F; Pierpaoli S; Provinciali M
Methods Mol Biol; 2008; 423():473-85. PubMed ID: 18370223
[TBL] [Abstract][Full Text] [Related]
32. Does lens intrinsic membrane protein MP19 contain a membrane-targeting signal?
Chen T; Li X; Yang Y; Erdene AG; Church RL
Mol Vis; 2003 Dec; 9():735-46. PubMed ID: 14735063
[TBL] [Abstract][Full Text] [Related]
33. A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas.
Gu XG; Schmitt M; Hiasa A; Nagata Y; Ikeda H; Sasaki Y; Akiyoshi K; Sunamoto J; Nakamura H; Kuribayashi K; Shiku H
Cancer Res; 1998 Aug; 58(15):3385-90. PubMed ID: 9699670
[TBL] [Abstract][Full Text] [Related]
34. Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity.
Dela Cruz JS; Trinh KR; Morrison SL; Penichet ML
J Immunol; 2000 Nov; 165(9):5112-21. PubMed ID: 11046042
[TBL] [Abstract][Full Text] [Related]
35. Protection against Mycobacterium avium by DNA vaccines expressing mycobacterial antigens as fusion proteins with green fluorescent protein.
Velaz-Faircloth M; Cobb AJ; Horstman AL; Henry SC; Frothingham R
Infect Immun; 1999 Aug; 67(8):4243-50. PubMed ID: 10417198
[TBL] [Abstract][Full Text] [Related]
36. Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA.
Wei WZ; Shi WP; Galy A; Lichlyter D; Hernandez S; Groner B; Heilbrun L; Jones RF
Int J Cancer; 1999 May; 81(5):748-54. PubMed ID: 10328228
[TBL] [Abstract][Full Text] [Related]
37. The mannosylated extracellular domain of Her2/neu produced in P. pastoris induces protective antitumor immunity.
Dimitriadis A; Gontinou C; Baxevanis CN; Mamalaki A
BMC Cancer; 2009 Oct; 9():386. PubMed ID: 19878568
[TBL] [Abstract][Full Text] [Related]
38. Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation.
Aigner A; Juhl H; Malerczyk C; Tkybusch A; Benz CC; Czubayko F
Oncogene; 2001 Apr; 20(17):2101-11. PubMed ID: 11360194
[TBL] [Abstract][Full Text] [Related]
39. Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development.
Charles LG; Xie YC; Restifo NP; Roessler B; Sanda MG
World J Urol; 2000 Apr; 18(2):136-42. PubMed ID: 10854149
[TBL] [Abstract][Full Text] [Related]
40. Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor.
Foy TM; Bannink J; Sutherland RA; McNeill PD; Moulton GG; Smith J; Cheever MA; Grabstein K
Vaccine; 2001 Mar; 19(17-19):2598-606. PubMed ID: 11257398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
